Haoyunbang Secures RMB 40 Million Series C Funding Led by Boxing Capital to Enhance Online-Offline Integrated Fertility Services
HaoYunBang Offline Clinic (Image provided by the enterprise)
VCBeat (WeChat ID: vcbeat) has learned that on December 26, Haoyunbang, a chain of specialized fertility clinics, officially announced the completion of a new round of financing amounting to RMB 40 million. The round was led by Boxing Capital, with Chongshan Capital continuing as a follow-on investor.
Haoyunbang was founded in 2014 and previously secured three rounds of financing from Genesis Capital, Puhua Capital, Sinovation Partners, and Chongshan Capital. Following this round of financing, the company remained committed in 2019 to an integrated online-offline strategy, continuing to refine its chain store operations while steadily expanding its online internet traffic.
Haoyunbang has always been dedicated to addressing users’ challenges in achieving pregnancy, with a deep focus on the field of assisted reproduction. It is a specialized chain medical service provider in the reproductive health sector that integrates online internet platforms with offline physical facilities. The company is committed to consolidating expert resources in the reproductive field and, through its self-established reproductive specialty clinics, systematically connecting various resources and stages across the infertility care continuum. It provides professional, rigorous, reassuring, and reliable fertility solutions for women experiencing difficulties in conceiving or carrying pregnancies to term.
In 2018, Haoyunbang’s chain of specialized outpatient clinics had expanded to Beijing, Jinan, Wuhan, and other cities, partnering with multiple surgical centers and reproductive medicine centers. Adhering to the service philosophy of “integrating management with treatment,” the specialized clinics deeply engage in pathway management throughout patients’ diagnosis and treatment processes. By leveraging physician groups and partner hospitals, they achieve more effective clinical outcomes across multiple stages of care, ultimately improving pregnancy success rates and enhancing patient service experience.
Furthermore, the Haoyunbang team continues to refine its offerings in product standardization for chain clinic operations, medical service process management, underlying SaaS system development, and online traffic conversion, thereby supporting future growth and expansion.
HaoYunBang’s online platform is a leading internet platform in China’s infertility and sterility sector, featuring a comprehensive matrix of internet products and commanding top-tier traffic resources in its niche segments. As of December 2018, it had accumulated over 7 million users and published more than 500,000 professional articles and case studies. The official website receives over 50,000 unique daily visits. Its WeChat official account, “Reproductive Medicine Space,” is widely recognized by professionals for its substantial user base and influence within the reproductive healthcare segment.
It has been learned that the platform also covers nearly 10,000 physicians in the field of reproductive medicine and has established deep strategic partnerships with multiple leading reproductive centers and pharmaceutical companies. The online platform effectively supports customer acquisition and the cold start of offline specialty clinics, helping them rapidly reach break-even and achieve revenue growth.
Huang Sen, founder of Haoyunbang, stated, “Struggling to conceive and dealing with infertility is an profoundly distressing journey. For many patients, the condition persists for more than a year, often extending over several years. Coupled with the complexity of diagnosis and treatment, it is extremely challenging for patients to independently identify the underlying causes and effective solutions, entailing significant costs. The value of Haoyunbang lies in addressing users’ core needs by providing not merely isolated treatments for individual conditions, but rather comprehensive, coherent, and compassionate solutions ultimately leading to successful pregnancy.”
“Success rate is the primary concern for our clients. Therefore, we are committed to optimizing departmental structures and service offerings by focusing on matching clients with the most suitable specialists, ensuring rational treatment pathways, and helping clients achieve optimal physical and mental conditions, thereby genuinely improving success rates. Healthcare is a serious industry; the deeper we engage in this field, the more we appreciate the challenges faced by our clients and recognize the value of our enterprise. We hope our team will continue to refine our service processes with dedication, extending our compassionate medical services to more clients and helping them fulfill their dreams of parenthood,” stated Huang Sen.
As the lead investor in this funding round, Zhang Lan, Partner at Boying Capital, stated, “We are optimistic about the growth prospects of the assisted reproductive technology (ART) industry. Private chain clinics can leverage their differentiated advantages in long-term patient management, personalized diagnosis and treatment, convenience, service experience, and privacy, thereby serving as a valuable complement to public hospitals. The core team of Haoyunbang possesses combined expertise in healthcare and the internet. The founder and several partners are alumni of Peking University Health Science Center, bringing professional medical backgrounds, deep-rooted experience in the field of infertility, and strong execution capabilities. We look forward to the company continuing to deliver superior therapeutic outcomes and services to more patients.”
Boxing Capital is a venture capital firm specializing in early-stage healthcare investments, founded by partners with extensive experience in healthcare industry investing. The firm currently manages funds totaling RMB 1 billion and has strategically invested in more than 30 innovative medical device and healthcare service companies with significant market potential. Boxing Capital’s limited partners include leading Chinese fund-of-funds, healthcare entrepreneurs, and seasoned investors.
Related Reports: